[Feature Stock] Samchundang Pharm Becomes "Hwangjejeu" During Intraday Trading... Six-Day Rally Continues
On March 24, Samchundang Pharm achieved the status of a "Hwangjejeu" (imperial stock), with its share price surpassing 1 million won per share during intraday trading.
As of 9:43 a.m. on this day, Samchundang Pharm was trading at 979,000 won, up 4.04% from the previous session. Shortly after the market opened, it reached 1,025,000 won, breaking through the 1 million won threshold per share.
Samchundang Pharm has been on a six-day winning streak since March 17. On March 20, when the company announced that it had completed the application for European Phase 1 and 2 clinical trials of its oral insulin, its stock surged more than 14%, overtaking Ecopro to become the largest company by market capitalization on KOSDAQ for the first time.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
At that time, Wi Haejoo, a researcher at Korea Investment & Securities, described Samchundang Pharm as the "catfish of KOSDAQ" and a "momentum powerhouse," noting that the company had achieved three momentum events in the first quarter alone. The results of the European Phase 1 and 2 clinical trial applications are expected to be available by the end of the year. The researcher emphasized, "If successful, the company will be closer to becoming the first in the world to develop oral insulin, attracting attention as a game changer in the market."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.